The Spanish Association of Pediatrics has as one of its main objectives the dissemination of rigorous and updated scientific information on the different areas of pediatrics. Annals of Pediatrics is the Body of Scientific Expression of the Association and is the vehicle through which members communicate. The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. CiteScore measures average citations received per document published. Read more.
|Published (Last):||4 March 2018|
|PDF File Size:||8.89 Mb|
|ePub File Size:||14.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
Maria de Lourdes L. Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms MPN , according to the 4th edition of the World Health Organization WHO classification are clonal diseases of hematopoietic stem cells, in which there is increased proliferation of the myeloid series granulocytic, erythrocytic, megakaryocytic series or mast cells with effective maturation.
The progression of all is characterized by marrow fibrosis or leukemic transformation. Some clinical aspects, the pathophysiology and diagnostic criteria of MPNs are presented in this paper. Key words: Myeloproliferative disorders; chronic myeloid, leukemia, polycythemia vera; thrombocythemia, essential; primary myelofibrosis; mutation.
Hemograma : pacientes na FC apresentam habitualmente anemia, leucocitose e plaquetometria normal ou aumentada.
Pode haver eosinofilia. A sobrevida varia de 3 a 10 anos. Osteoesclerose pode estar presente. Trombocitemia essencial TE. DHL aumentado; e 5. Anormalidades tais como del 5q , t 3;3 q21;q26,2 e inv 3 q21q Sangramento mucoso ou de trato gastrointestinal podeser observado.
World Health Organization Classifications of Tumours. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. Chronic myeloid leukemia: a disease of youth in Brazil. Leuk Res 34 4 Sawyers CL. Chronic myeloid leukemia. N Engl J Med. Van Etten RA. Chauffaille MLLF. Rev Bras Hemato Hemoter ;30 supl I Clinical implications of der 9q deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia.
Cancer Genet Cytogenet. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Am J Hematol ;83 4 Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. Goldman JM. How I treat myeloid leukemia in the imatinib era. Myeloproliferative disorders. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.
An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia.
Br J Haematol. Orazi A. JAK2VF mutation in patients with catastrophic intraabdominal thormboses. Am J Clin Pathol. How I treat patients with polycythemia vera. The myomatous erythtocytosis syndrome: a review.
Obstet Gynecol. Skoda R. The genetic basis of myeloproliferative disorders. Tefferi A, Gilliland G. Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system. Best Pract Res Clin Haem. Hoffman R, Rondelli D. Biology and treatment of primary myelofibrosis. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Mesa R. Navigationg the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Coussinier-Paris P. Schwartz RS. The hypereosinophilic syndrome and the biology of cancer. Eosinophilia: secondary, clonal and idiopathic. Hypereosinophilic syndrome: lymphoproliferativa and myeloproliferative variants. Sem in resp and critical care med.
Fletcher S, Bain B. Diagnosis and treatment of hypereosinophilic syndromes. Curr Opin Hematol. All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License. Services on Demand Journal. Chauffaille Livre-docente. ABSTRACT Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms MPN , according to the 4th edition of the World Health Organization WHO classification are clonal diseases of hematopoietic stem cells, in which there is increased proliferation of the myeloid series granulocytic, erythrocytic, megakaryocytic series or mast cells with effective maturation.
How to cite this article.
¿Qué causa los síndromes mielodisplásicos?
Skip to search form Skip to main content You are currently offline. Some features of the site may not work correctly. Save to Library. Create Alert. Launch Research Feed. Share This Paper. Topics from this paper.